Related Experiment Video
Updated: Jul 10, 2026
10:21
Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix
Published on: June 14, 2016
Upregulation of myocardial Annexin A5 in hypertensive heart disease: association with systolic dysfunction
Susana Ravassa1, Arantxa González, Begoña López
1Division of Cardiovascular Sciences, Centre for Applied Medical Research, University of Navarra, Pamplona, Spain.
European Heart Journal
|September 4, 2007
Summary
Myocardial Annexin A5 (AnxA5) upregulation is linked to hypertensive heart disease (HHD) and reduced systolic function, independent of apoptosis. Plasma AnxA5 may indicate myocardial AnxA5 levels and dysfunction in HHD patients.
Area of Science:
- Cardiology
- Molecular Biology
- Biochemistry
Background:
- Hypertensive heart disease (HHD) involves cardiac remodeling and dysfunction.
- The role of Annexin A5 (AnxA5) in HHD pathogenesis is not fully understood.
- Apoptosis is a known contributor to cardiac dysfunction in various heart diseases.
Purpose of the Study:
- To determine the association between Annexin A5 (AnxA5) and hypertensive heart disease (HHD).
- To investigate if this association is dependent on apoptosis.
- To explore the potential of plasma AnxA5 as a biomarker in HHD.
Main Methods:
- Quantification of myocardial and plasma AnxA5 using RT-PCR, Western blot, immunohistochemistry, and ELISA.
- Assessment of apoptosis via DNA fragmentation, caspase-3 activation, and PARP/Bax/Bcl-2 ratios.
- Correlation analysis between AnxA5 levels, cardiac function parameters, and apoptosis markers in hypertensive patients across different disease stages.
Main Results:
- Myocardial and plasma AnxA5 levels were elevated in hypertensive patients with left ventricular hypertrophy (LVH) and heart failure (HF) symptoms (stages B and C) compared to normotensives and stage A.
- Myocardial AnxA5 inversely correlated with systolic function, independent of apoptosis.
- Plasma AnxA5 correlated with myocardial AnxA5 and inversely with systolic function.
Conclusions:
- Myocardial AnxA5 upregulation is associated with HHD and impaired systolic function in hypertensive patients.
- This association is independent of apoptotic mechanisms.
- Plasma AnxA5 may serve as a non-invasive marker for myocardial AnxA5 upregulation and systolic dysfunction in HHD.
Related Concept Videos
01:17Pathophysiology of Heart Failure
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:20Mitral Regurgitation I: Introduction
Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
01:29Hypertension II: Pathophysiology
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...